Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08032562 in Advanced or Metastatic Solid Tumors
NCT07318805Phase 1Recruiting
- Sponsor
- Pfizer
- Start
- Dec 2025
- Primary completion
- Apr 2029
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of PF-08032562 in breast cancer and colorectal cancer (CRC) (7 cohorts), sponsored by Pfizer. Primary endpoints: Dose-Limiting Toxicities at 28 days, Laboratory Abnormalities and 2 more. Started Dec 2025; status: recruiting.
02
Drugs
PF-08032562
03
Conditions
breast cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07318805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07318805.